Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDP1867
- Development stage
- Phase 1
- Lead developer
- Evelo Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EDP1867 is an investigational **oral microbial therapy** from **Evelo Biosciences** for inflammatory disease, principally **atopic dermatitis**. Public sources describe it as an **orally administered pharmaceutical preparation of a single strain of bacteria**, formulated as capsules and developed within Evelo's small-intestinal-axis microbiome platform. In a completed first-in-human **Phase 1a/1b** study in healthy volunteers and patients with moderate atopic dermatitis, with optional psoriasis and mild asthma cohorts, EDP1867 was reported to be **safe and well tolerated** across tested doses; however, Evelo later stated there was **no clear evidence of clinical benefit** in the small analyzable atopic dermatitis subset and the program was **put on hold**. Preclinical material cited anti-inflammatory activity in a **Th2-driven atopic dermatitis mouse model**, but the precise molecular target and human mechanism remain publicly undisclosed.
Beyond the preview
Go deeper on EDP1867.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDP1867.